Conceptos Básicos
BTK inhibitors play a crucial role in mantle cell lymphoma treatment, with evolving options and considerations for frontline and relapsed cases.
Estadísticas
The overall response rate associated with single-agent ibrutinib was 66%, with a complete response rate of 17%, and a median progression-free survival of around 14 months.
Acalabrutinib reported an overall response rate of 81%, with a complete response rate of 40%, and a median progression-free survival of 22 months.
Zanubrutinib showed an overall response rate of 84%, with a complete response rate of 78%, and a median progression-free survival of 33 months.
Pirtobrutinib demonstrated an overall response rate of approximately 58%, with a complete response rate of 20%, and a median duration of response of around 22 months.
Citas
"In general, most of us in the field feel that the efficacy is likely very similar across these three covalent BTK inhibitors." - Dr. Anita Kumar
"We favor the use of second-generation BTK inhibitors like acalabrutinib and zanubrutinib, which have been associated with fewer adverse events compared to ibrutinib." - Dr. Anita Kumar
"It's early days in terms of the study — our primary endpoint is 2-year progression-free survival — but we're encouraged by the early results." - Dr. Anita Kumar